Filing Details

Accession Number:
0001213900-23-093858
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-06 21:45:07
Reporting Period:
2023-12-04
Accepted Time:
2023-12-06 21:45:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
819050 Fresh Tracks Therapeutics Inc. FRTX Biological Products, (No Disgnostic Substances) (2836) 930948554
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1799866 Exploration Capital Fund, Lp 250 East 200 South
Floor 16
Salt Lake City UT 84111
No No No No
2003481 Exploration Capital General Partner, Llc 250 East 200 South, Floor 16
Salt Lake City UT 84111
No No No No
2003514 Exploration Capital, Llc 250 East 200 South, Floor 16
Salt Lake City UT 84111
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-12-04 7,579 $0.85 677,579 No 4 P Direct
Common Stock Disposition 2023-12-05 5,188 $0.85 682,767 No 4 P Direct
Common Stock Disposition 2023-12-06 17,233 $0.90 700,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
Footnotes
  1. Exploration Capital, LLC ("X-Cap") is the investment manager of Exploration Capital Fund, LP (the "Partnership") and as a result may be deemed to be the beneficial owner of all the securities held by the Partnership. Exploration Capital General Partner, LLC (the "GP") is the general partner of the Partnership and as a result may be deemed to be the beneficial owner of all the securities held by the Partnership.
  2. Stephen L. Gustin is the Managing Partner of X-Cap and as a result may be deemed to be the beneficial owner of all the securities held by the Partnership. Mr. Gustin disclaims beneficial ownership of the reported securities held by the Partnership except to the extent of his pecuniary interest.